0001562180-18-004778.txt : 20181203 0001562180-18-004778.hdr.sgml : 20181203 20181203182540 ACCESSION NUMBER: 0001562180-18-004778 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181203 FILED AS OF DATE: 20181203 DATE AS OF CHANGE: 20181203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MURDOCK TERRY L CENTRAL INDEX KEY: 0001274071 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 181215057 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 79 T.W. ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: P. O. BOX # 110341 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2018-12-03 false 0001560241 G1 Therapeutics, Inc. GTHX 0001274071 MURDOCK TERRY L 79 T.W. ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 false true false false SVP of Development Operations Common Stock 2018-12-03 4 M false 3523.00 13.51 A 3523.00 D Common Stock 2018-12-03 4 S false 3523.00 38.5408 D 0.00 D Stock Options (Right to Buy) 13.51 2018-12-03 4 M false 3523.00 0.00 D 2027-08-01 Common Stock 3523.00 82401.00 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The price represents the weighted average price with a low of $38.25 and a high of $38.74. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. The shares underlying this option vested as to 25% of the shares on August 1, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. /s/ James Stillman Hanson, attorney-in-fact 2018-12-03